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Abstract
The objective of the study is to assess effectiveness and safety of minimally invasive lumbar
interbody fusion (MILIF) for degenerative lumbar disorders (DLD) in daily surgical practice and
follow up with patients for one year after surgery.
A prospective, multicenter, pragmatic, monitored, international outcome study in patients with
DLD causing back/leg pain was conducted (19 centers). Two hundred fifty-two patients received
standard of care available in the centers. Patients were included if they were aged >18 years,
required one- or two-level lumbar fusion for DLD, and met the criteria for approved device
indications. Primary endpoints: time to first ambulation (TFA) and time to surgery recovery
(TSR). Secondary endpoints: patient-reported outcomes (PROs)--back and leg pain (visual
analog scale), disability (Oswestry Disability Index (ODI)), health status (EQ-5D), fusion rates,
reoperation rates, change in pain medication, rehabilitation, return to work, patient
satisfaction, and adverse events (AEs). Experienced surgeons (≥30 surgeries pre-study) treated
patients with DLD by one- or two-level MILIF and patients were evaluated for one
year (NCT01143324).
At one year, 92% (233/252) of patients remained in the study. Primary outcomes: TFA, 1.3 ±0.5
days and TSR, 3.2 ±2.0 days. Secondary outcomes: Most patients (83.3%) received one level
MILIF; one (two-level) MILIF mean surgery duration, 128 (182) min; fluoroscopy time, 115 (154)
sec; blood loss, 164 (233) mL; at one year statistically significant (P<.0001) and clinically
meaningful changes from baseline were reported in all PROs--reduced back pain (2.9 ±2.5 vs.
6.2 ±2.3 at intake), reduced leg pain (2.2 ±2.6 vs. 5.9 ±2.8), and ODI (22.4% ± 18.6 vs. 45.3% ±
15.3), as well as health-related quality of life (EQ-5D index: 0.71 ±0.28 vs. 0.34 ±0.32). More of
the professional workers were working at one year than those prior to surgery (70.3% vs. 55.2%).
Three AEs and one serious AE were considered procedure-related; there were no deep site
infections or deaths.
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This is the first study evaluating MILIF for treatment of DLD in daily clinical practice. Clinically
significant improvements were observed in all endpoints. Short-term post-surgery
improvements (four weeks) were maintained through one year with minimal complications.
Our results suggest that MILIF has good-to-excellent outcomes for the treatment of DLD in a
broad patient population under different clinical conditions and healthcare delivery systems.
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Introduction
In the past 25 years, minimally invasive spine surgery (MIS) has emerged as an alternative to
traditional open surgery to treat degenerative lumbar diseases (DLD). MIS allows less extensive
manipulation of surrounding tissues while accomplishing the same goals and objectives for
target tissues [1-2]. Short-term benefits of MIS include reductions in intraoperative blood loss,
postoperative pain, approach-related soft tissue damage and duration of hospital stay vs open
methods. MIS is also associated with earlier ambulation and an increased proportion of
patients returning to work vs. open surgeries [3-5].
Published, long-term MIS studies have been associated with one or more of the following study
limitations: low number of patients, surgeries performed at a single site using a single surgical
technique, retrospective observational design, variability in reporting and surgeon learning
curve [4, 6-13]. While available data suggests decreased morbidity and at least comparable
outcomes vs. open surgeries for the immediate and short-term postoperative period [14], there
is limited data to support the long-term superiority of MIS over open techniques [3]. 
A multicenter study reflecting the usual surgical practice was required to observe outcomes and
effectiveness of the minimally invasive techniques performed by experienced surgeons.
Purpose of the study
The objectives of the MASTERS-D study were to observe patients undergoing minimally
invasive lumbar interbody fusion (MILIF) short-term recovery of one year to document and
evaluate the clinical and radiological patient outcomes in both short-term duration (post-
operative, four weeks) [5] and mid-term duration (one year) after MILIF using posterior lumbar
interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) techniques for the
treatment of DLDs in a broad patient population. 
Materials And Methods
The study methodology has been described in a previous publication by the authors in Pereira
et al [5].
Study environment
The study was initiated by a group of experienced surgeons and conducted in 19 centers across
14 countries (Europe, Canada, and the Middle East). To avoid a potential learning curve effect,
all participating surgeons were required to have performed ≥30 pre-study minimally invasive,
instrumented lumbar interbody fusion procedures for DLD and surgical indications. Surgical
indications, protocols, follow-up length, monitoring, and data analysis were decided before the
study was initiated. Each surgeon was asked to contribute a maximum of 30 consecutive
patients from their clinic at the start of the study, and each clinical center had a research nurse
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participating for the collection of data. The study group met regularly (quarterly) over the
internet to discuss progress, barriers, or problems. The sponsor (Medtronic) of the study
participated in the monitoring of the data, but did not participate in the study design or had
any input in the analysis of results.
Study design and patients
MASTERS-D was a prospective, international, observational study with a one-year follow-up
and monitored (NCT01143324) patients with DLD causing back/leg pain referred to a surgical
practice with experienced surgeons. All patients who met the inclusion criteria and were willing
to participate in the study were enrolled consecutively in order to reduce selection bias. All
patients received routine standard of care according to hospital protocol to reflect the real life
practice circumstances, and all patients signed an informed consent/patient data release form.
Monitoring
Monitoring visits were conducted throughout the study by monitors from Medtronic and
independent professionals from clinical research organizations (CROs). This approach aimed to
ensure compliance with protocol, adherence to data collection procedures, accuracy of
submitted clinical data, and verify proper maintenance of records for the duration of the study.
Ethics Approval
Ethics committee (EC), institutional review board (IRB), human research ethics committee
(HREC) requirements varied across centers and countries. The study was conducted in
compliance with the latest version of the Declaration of Helsinki, and laws and regulations of
the countries in which the study was conducted, including data protection laws and the Clinical
Investigation Plan. The EC, IRB, HREC, data protection authority, and Competent Authority
approvals received were as follows: 1. Klinikum Amstetten, Ethikommission fur das Bundesland
Niederosterreich am Sitz des Amtes der NO Landesregierung, Abteilung Sanitats und
Krankenanstaltenrecht, Austria; 2. O.L.V.Aalst, Local Ethisch Comite, OL Vrouwziekenhuis
Aalst, Belgium; 3. Horizon Health Network, East Spine Center, Local Research Ethics Board,
Canada; 4. Universitatsklinikum Freiburg, Central ethics committee (Universität Freiburg,
Germany); 5. Mediterraneo Hospital, Local ethics committee, Notification to local authority,
submission to Data Protection Authority; 6. Tel Aviv Sourasky Medical center, Local Ethics
committee, Tel Aviv Medical Center, Israel and Hospital director; 7. Istituti Ortopedici Rizzoli,
Comitato Etico Scientifico, Istituto Rizzoli di Bologna, Italy; 8. Fatebenefratelli Hospital,
Comitato Etico Scientifico, Ospedale Fatebenefratelli, Italy; 9. Medical University of Gdansk,
Local independent medical ethic committee for scientific research of Gdansk University,
Poland; 10. Hospital S Joao, Local comissao de etica do Hospital S Joao, Portugal and
Submission to Data Protection Authority; 11. Ustredna vojenska nemocnica SNP, Eticka
Komisia, Ustrednex Vojenskej Nomocnice SNP, Slovakia; 12. Hospital Clinic de Barcelona,
Comite de investigacion del hospital Clinic de Barcelona, Spain; 13. Guys & St. Thomas NHS
Trust, Local NHS National Ethics Service, UK. The following centers did not require ethics
committee approval by a local agency, and investigator statements were collected and
confirmed by investigators: 1. Karvinska hornicka nemocnice, Czech Republic; 2. Klinikum
Kulmbach, Germany, 3. Universitatsklinikum Magdeburg, Germany; 4. Marienhaus Klinikum,
Germany; 5. Franziskus Ziekenhis Roosendaal, Netherlands; 6. Bergman Clinics, Netherlands;
7. London Bridge Hospital, Ethics Committee.
Eligibility Criteria
Eligibility criteria were broad and based on the approved indications for the devices used in this
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study. Inclusion criteria were: eligible patients aged >18 years were clinically assessed as
requiring a single- or double-level instrumented lumbar fusion for the treatment of the
degenerative lumbar spine. All patients were offered to participate in the study and planned to
undergo the fusion procedure using PLIF or TLIF techniques to receive a CD Horizon Spinal
System (Medtronic Sofamor Danek Inc., Memphis, TN, USA) via the MAST approach (Minimal
Access Spinal Technologies, Medtronic Sofamor Danek USA, Inc.) in accordance with the device
label. Exclusion criteria were: patients who had previously undergone extensive open lumbar
spine surgery other than microdiscectomy were excluded from the study, as were patients with
indications for a procedure other than DLD.
Surgical Procedures
The definitions applied as per study protocol are presented in Table 1. The muscle sparing,
minimally invasive approach could be performed unilaterally or bilaterally for instrumentation
and spinal decompression at the surgeon’s discretion. One or two cages were placed in the
intervertebral space to maintain or restore disc height. To achieve interbody fusion, bone grafts
and/or substitutes were used. The posterior stabilization of the treated spinal segments was




Surgical technique using a midline approach and requiring a partial or complete detachment of the lumbar




Muscle-sparing surgical technique using an intermuscle- or transmuscle-splitting approach, minimizing




Instrumentation placement using direct vision of target structures via an intermuscle-splitting approach
Percutaneous
technique
Instrumentation placement using radiographic or navigation guidance via stab incisions without direct vision
of target structures
TABLE 1: Surgical techniques and instrumentation definitions for posterior lumbar
surgery and instrumentation according to the study protocol
Endpoints and study assessments
The primary objectives of the study were to observe and document patient short-term recovery
after surgery [5] which included: a) time to first ambulation (TFA) (defined as the number of
days after surgery before patients were able to get out of bed and ambulate with or without
assistance), and b) time to surgery recovery (TSR) (defined as the number of days after surgery
until patients no longer needed intravenous infusion of analgesic drugs, had no surgery-related
complications/adverse events (AEs) impeding discharge, and no longer needed nursing care).
Secondary outcomes were defined as patient-reported outcomes (PRO) and radiological
outcomes one year after surgery; PROs included back and leg pain intensity measured by visual
analog scale (VAS) scores [15] Oswestry disability index (ODI) scores [16], and EuroQoL five
dimension (EQ-5D) scores [17]. Back and leg pain were assessed on a 10 cm VAS scale (0 = no
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pain, 10 = the worst possible pain) preoperatively, during the hospital stay, at surgery recovery
day, at day two after surgery, at discharge, and at all follow-up visits. Disability was rated on a
0% to 100% scale preoperatively and postoperatively at all follow-up visits using the ten-item
ODI (0% = minimal disability, 100% = maximal disability); ODI was recognized by Mapi
Research trust. Health related quality of life was assessed pre-operatively and at all follow-up
visits using the five-item EQ-5D questionnaire (if it was part of standard of care at the study
center) with three levels for each dimension: no problems, some problems, or extreme
problems. EQ-5D index scores were obtained using the UK population value set
(http://www.euroqol.org). In addition, patients completed the EQ-VAS to self-rate their overall
health state on a 0 to 100 scale (0 = maximal health-related problems, 100 = minimal health-
related problems).
Clinical and radiological outcomes included the documentation of AEs and fusion rate
assessment at one year after surgery. The fusion rate was assessed via computed tomography
(CT) scan or X-rays at those sites where this assessment was part of standard of care. As per
protocol for assessment by CT, the criteria for fusion was bony bridging, and when assessed
through X-rays the criteria were bony bridging, <4° motion in flexion/extension views, and
integrity of implanted devices. Other clinical endpoints assessed were: documentation of
rehabilitation and return to work; reoperation rates, defined as the proportion of patients
needing a second intervention at the treated level(s) within one year; proportion of patients
needing intervention at an adjacent level; patient satisfaction as assessed by the surgeon; and a
change in consumption of pain medication over time compared with baseline. Work status was
assessed at the preoperative visit, at 4 weeks and 3, 6, and 12 months postoperatively [11].
Data were collected prospectively by the investigators (surgeons) or the study nurses as per
standard of care for each center and included patient medical history, preoperative data,
assessment of time from surgery to TFA, TSR and time to discharge. The objective of the TSR
day assessment is to record the day when the patient could be discharged based on his actual
clinical condition. In some cases the effective day of discharge may be prolonged by factors
other than the patient's clinical recovery such as social factors, reimbursement issues, and/or
hospital protocol, in these cases the discharge day was not recorded. Postoperative follow-up
visits by the treating surgeon were performed according to standard hospital routine with the
recommended schedule of a visit at 4 weeks, and 3, 6, and 12 months postoperatively.
Adverse Events
AEs and serious AEs (SAEs) were defined as “any untoward medical occurrence in a subject”,
and “an AE that led to death, led to serious deterioration in the health of a subject, led to fetal
distress, death or congenital abnormality” respectively. All investigators/surgeons classified the
AEs in seriousness and its relation to the surgery, MAST approach, and device (unrelated,
unlikely, possibly, probably or definitely). For reporting purposes, all AEs were classified into
lowest level terms following the medical dictionary for regulatory activities terminology
(MedDRA), version 15.1 (V15.1).
Statistical analysis
For continuous variables, summary statistics were calculated together with the number of
missing and non-missing values. For categorical variables, absolute and relative frequencies
(based on non-missing values) were provided. The change in each PRO score was calculated for
all patients with a valid observation of both the preoperative and four-week score of the PRO in
concern. Changes from baseline in PROs at four weeks postoperatively were analyzed
(depending on the Shapiro-Wilk test results on normality) using the two-sided t-test for paired
comparisons and the Wilcoxon signed rank test with a significance level of 0.05. A similar
strategy was used to evaluate changes between baseline and other follow-up scores, and results
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are presented as mean (± standard deviation (SD)). 
Results
Center contribution
Contributing surgeons at each center were instructed to contribute 10-30 consecutive
degenerative disk disorder (DDD) patients. Once the maximum number of patients had been
attained the center participation for new patients was closed, and only follow up activities
proceeded for one year.
Patient disposition and baseline demographics
A total of 252 patients underwent an MIS procedure of which 233 (92%) patients remained at
follow-up for one-year post-surgery. Eleven patients (4.4%) were lost to follow-up, four
withdrew (1.6%), and four (1.6%) were explanted resulting in a total of 19 patients who were
unavailable for follow-up at one-year post-surgery. Characteristics of the total MIS population
were as follows: 56.3% of patients were female; mean age was 53.8, ±11.8 years; mean body
mass index (BMI) was 27.7, ±4.6 kg/m2; mean duration of symptoms resulting in planned
surgery was 28.5, ±38.2 months; mean duration of conservative treatment was 20.7, ±34.3
months; and the main indications for surgery were leg pain (52%), back pain (38.9%), and
neurogenic claudication (9.1%). Patient demographics are shown in Table 2. Spondylolisthesis
(52.8%), stenosis (71.4%), and disc pathology (93.7%) were the most common preoperative
degenerative lumbar pathologies. Of the spondylolisthesis cases, 69% were degenerative, 84%
were Grade 1, and 16% were Grade 2 according to the Meyerding classification. 
Total number of patients 252
Gender (% females) 56.3
Mean (±SD) age (y) 53.8 (±11.8)
Mean (±SD) BMI (kg/m2) 27.7 (±4.6)
Mean (±SD) duration of symptoms resulting in planned surgery (mo) 28.5 (±38.2)
Mean (±SD) duration of conservative treatment (mo) 20.7 (±34.3)
Pre-existing conditions relevant to study (%) 37.3%
Previous lumbar surgeries (%) 15.1%
At target level:  
Microdiscectomy open surgery 3.2%
Microdiscectomy minimally invasive surgery 9.1%
Decompression (minimally invasive surgery) 3.6%
TABLE 2: Patient demographics and baseline characteristics
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Surgical procedures performed
One-level surgery was performed in 83.3% (210/252) patients; of these, the majority of cases
(90.5%) were interbody fusion at the L4−L5 or L5−S1 levels. 16.7% (42 patients) underwent two-
level surgery, where fusion was most frequently (73.8%) performed at L4–S1.
First level surgical approaches varied substantially. Unilateral mini-open approaches were more
commonly performed (61.9%) either without decompression of neural structures (18.3%) or
with unilateral (36.5%) or bilateral (7.1%) decompression. Bilateral mini-open approaches
(38.1%) were performed without decompression (5.2%) or with unilateral (24.6%) or bilateral
(8.3%) decompression.
A minority of surgeons reported the use of a navigation system (i.e., pre-CT scan (3.6%), 3D
fluoroscopy (1.6%), image fusion technique (2.4%), and O-arm imaging (5.6%) (Table 3). Most
fixation techniques were bilateral percutaneous (48.8%) or bilateral mini-open (39.7%). For the
interbody fusion, most surgeries used an autograft 75.0% (189/252), while 15.9% (40/252) used
allograft bone bank, and 45.5% of the autograft were used in conjunction with nanocrystalline
hydroxyapatite (86/189).
Mean (±SD) surgery duration (min) 136.8 (±50.4)
             One level 127.7 (±43.5)
             Two level 182.0 (±58.3)
Mean (±SD) estimated blood loss (mL) 175.8 (±160.1)
             One level 163.9 (±139.7)
             Two level 233.1 (±229.0)
Blood transfusion, n (%) 1 (0.4)
Mean (±SD) total fluoroscopy time (sec) 122 (±130.7)
             One level 115.1 (±123.9)
             Two level 154.1 (±156.6)
Navigation system used, n (%)  
Pre-CT 9 (3.6)
3D fluoroscopy 4 (1.6)
Image fusion technique 6 (2.4)
O-arm imaging 14 (5.6)
Prophylactic antibiotics prescribed, n (%) 248 (98.4)




Across 252 patients, the mean TFA was 1.3 ±0.5 days, the mean TSR was 3.2 ±2 days, and the
mean time to discharge was 6.3 days [5].
Secondary Outcomes at One-Year Follow-Up (PRO)
Statistically significant and clinically meaningful changes were reported postoperatively as
early as four weeks and were maintained or further improved over one year for each of the
PROs assessed. From baseline to one year, there was a 3.3 and 3.8 points improvement in back
(2.9 ±2.5 vs. 6.2 ±2.3) and leg pain intensity (2.2 ±2.6 vs. 5.9 ±2.8) respectively, (P <.0001; Figure
1). Clinical success in reducing back pain was defined as a minimal change in back pain (≥30%
improvement from baseline or a change of ≥1.5 on a 0–10 VAS scale) [18] and was achieved at
two days after surgery by 46% and 53% of patients respectively. This increased throughout the
study to more than 70% and 72% of patients by one year, respectively. Considering the above-
mentioned thresholds for leg pain, clinical success was achieved by 69% and 69% of patients at
two days after surgery, increasing to 73% and 74% of patients at one year respectively.
Statistically significant reductions in ODI were reported beginning at four weeks and continued
through one year, reaching an improvement in score of 22.4% ±18.6 vs. baseline (45.3% ±15.3),
(P <.0001; Figure 2). Minimally important changes (≥30% improvement from baseline or
improvement in ODI score of ≥10) in disability were achieved by more than 41% and 51% of
patients respectively at four weeks which increased to more than 70% and 77%, respectively by
one year.
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FIGURE 1: Improvement of back and leg pain.
Back (a) and leg (b) pain intensity scores reported preoperatively and postoperatively on a 10
cm visual analog scale (VAS) where 0 = minimal pain intensity or pain frequency and 10 =
maximal pain intensity or pain frequency (total population, n=252). ***P < .0001 for difference
between preoperative (back 6.2 ±2.3, leg 5.9 ±2.8) and postoperative scores at two days (back
4.5 ±2.3, leg 2.6 ±2.7), surgery recovery day (back 3.9 ±2.2, leg 2.2 ±2.5), discharge (back 3.1
±2.1, leg 1.9 ±2.3), four weeks (back 2.9 ±2.2, leg 2.5 ±2.6), three months (back 2.9 ±2.2, leg 2.1
±2.4), six months (back 2.9 ±2.4, leg 2.0 ±2.4), and twelve months (back 2.9 ±2.5, leg 2.2 ±2.6).
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FIGURE 2: Improvement of patient disability.
Oswestry disability index (ODI) scores (calculated in %) reported preoperatively and at four
weeks and three, six, and twelve months postoperatively on a 0% to 100% scale, where 0% =
minimal disability and 100% = maximal disability (total population, n=252).***P < .0001.
Improvement in EQ-VAS scores vs. preoperative scores began at four weeks (12.0 points; P
<.0001) and reached 18.0 points at one year (P <.0001). At one year, the proportion of patients
who reported no health-related problems increased from the preoperative values in each of the
five individual EQ-5D domains: mobility (57.2% vs. 11.1%), self-care (75.4% vs. 54.3%), usual
activities (56.7% vs. 9.6%), pain/discomfort (30.3% vs. 1.4%), and anxiety/depression (69.6% vs.
49.5%) (Figure 3). For each domain, improvements were apparent as early as four weeks and
continued to increase through one year. The EQ-5D index improved from a mean of 0.34 ±0.32
preoperatively to 0.71 ±0.28 at one-year follow-up.
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FIGURE 3: Overall amelioration in quality of life.
Percentages of patients who reported on five EQ-5D domains preoperatively vs. four weeks,
three months, six months and twelve months.
Clinical and Radiological Surgery Outcomes
Assessment of fusion was not standard of care at all sites, and not all levels treated were
assessed for fusion success. One hundred thirty one-level and 24 two-level patients who were
assessed for fusion as per protocol at one year; the fusion rates were 90.8% (118/130) and 89.6%
(43/48) respectively. Some sites assessed fusion at one year, but used different site-specific
criteria than those set out in the protocol of this study; an additional 14 patients (11 one-level
and 3 two-level) were assessed using non-protocol defined criteria had fusion rates of 90.9%
(10/11 levels) and 100% (6/6 levels) respectively.
The rate of additional lumbar spinal surgeries was low at 2.8% (7/252) in seven patients at six
centers. Of these seven additional surgeries, three (1.2%) were reoperations (at the same level--
loss of pedicle screw fixation causing recurrent spondylolisthesis and left leg radiculopathy,
revision of right pedicle screw S1, vertebral body collapse of upper target vertebra), and four
(1.6%) were performed at an adjacent level (Disc herniation on upper adjacent level with
extrusion on the right side, pedicle screw dislocation because of osteoporotic bone and trauma,
intraspinal hemorrhage at one and two levels above the previously operated levels, and pre-
existing lower adjacent level of DDD).
Likely reflective of local clinical practice, fewer than half (45%, 102/226) of the patients were
receiving rehabilitation at three months. Assessed by the surgeon at one year, the satisfaction
with the results of treatment after the surgery was 81% (177/218), while 78% (171/218)
indicated to be helped by the treatment as expected, and 82% (178/218) indicated to have the
same treatment again for the same condition. At one year, the surgeons indicated that 85.8% of
the patients were completely improved (28%, 61/218), much improved (41%, 89/218), or slightly
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improved 17% (37/218) with regard to their back pain recovery compared to preoperative levels.
Ability to return to work (full- and part-time work) increased postoperatively among
professional workers which composed of 57% of the total patient population (143/252). At the
preoperative visit, 55.2% (79/143) were working, while at one year postoperatively, this number
climbed to 70.3% (90/128). The rate of professional workers being on paid leave/disability
because of back problems was halved from pre-op (57/143, 39.9%) to one year (22/128, 17.2%).
Even among patients who were still taking lumbar spine pain medications (68.7% pre-op vs
41.5% at one year), the frequency and potency of pain medication use decreased over the one
year after surgery vs. preoperative conditions (Figure 4).
FIGURE 4: Decreased frequency and potency of pain
medication for lumbar spine in the past week.
Percentages may not equal 100% because combinations of medications may have been used
by the same patient.
Adverse Events
Throughout the study, 50 AEs in 39 patients were considered by the investigator to be related to
surgery, MAST, or device. Nine of these were SAEs (acute allergic reaction, postoperative
confusion, leg pain, back pain, lumbar disc herniation, spinal hematoma, and urosepsis). Out of
these 50 AEs, 3 AEs (0.79%, 2/252) and 1 SAE (increased leg pain) were considered related to
the minimally invasive approach (Table 4); there was one superficial incision site abscess
related to surgery (0.4%), and there were no deep wound infections among the 252 patients.
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Count of total related to device, surgery, or MAST™ (serious
event)
Acute allergic reaction 0 1 (1)*
Back pain 0 7(1)*
Confusion postoperative 0 1 (1)*
Dural tear 0 4
Fever 0 2
Hypoesthesia 0 3
Implant site seroma 0 2
Implant site abcess 0 1
Leg pain         3 (1)* 10 (3)*
Lumbar disc herniation 0 1 (1)*
Lumbar radiculopathy 0 3
Nausea 0 4
Sacro-iliac pain 0 4
Spinal hematoma 0 1 (1)*
Urinary tract infection 0 3
Urosepsis 0 1 (1)*
Vertigo 0 1
Vomiting 0 1
Total 3(1) 50 (9)
TABLE 4: Adverse events in total population over twelve months
* Parentheses indicate a serious adverse event.
Discussion
We reported the one-year results of a pragmatic, multicenter, prospective, monitored study
using minimally invasive fusion strategies in the daily surgical practice setting in 19 countries.
Our results indicate that MILIF outcomes are in line with other reported surgical studies for the
spine and provide valuable insights into the management of DLD in the usual clinical practice.
This observational study did not add to the patient burden of illness and has gathered a large
network of surgeons who have cooperated to collect a comprehensive set of outcomes including
an assessment of long-term outcomes through the achievement of high levels of one-year
follow-up (92%).
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Short surgery duration and low blood loss achieved with MILIF at four weeks after surgery were
beneficial for patients as they aided in faster recovery [5]. These improved clinical results with
low complication and reoperation rates were maintained over the one year of the study.
Statistically significant and consistent results in all assessed PROs (VAS back and leg pain, ODI,
and EQ-5D) were seen from two days after surgery and were maintained throughout the one-
year study indicating reduced pain, better mobility, and improvements in quality of life.
Clinical success [18] was demonstrated in the rapid and persistent improvement in pain and
disability, which started as early as two days after surgery and was maintained or improved
throughout the one-year study. Reflective of the improvements in pain and disability, high
levels of patient satisfaction with surgery (81%) and reductions in both frequency and potency
of pain medications were observed vs. baseline over the one year after surgery. In addition, low
levels of formal rehabilitation at one year have been reported (27.0%). Reduction in the use of
pain medications after MIS are also consistent with previous reports [11, 14, 19-22]. In a
retrospective study, narcotic use decreased from 100% before MIS to 31% by six months
postoperatively [21]. Perioperative morphine use was significantly reduced after MIS TLIF vs.
open surgery [11] and patients who received MIS had a significantly faster narcotic
independence [22].
Patient well-being was indicated by an improvement in their disability and their ability to
return to work. At the one-year postoperative time point, the evaluation of work status included
both patients who had and had not been working prior to surgery. At one year, 70.3% (90/128)
of patients were working compared with 55.2% (43/79) at the preoperative assessment.
Moreover, the number of patients on paid leave/disability was halved in one year (39.9% down
to 17.2%).  Improvements in the ability to return to work in this study are in agreement with
published reports. In a long-term prospective study, more patients were working (>68%) at two
to six years after open or laparoscopic surgery for DDD than had worked preoperatively (52%)
[19]. Adogwa et al., 2011 [23] reported a faster return to work (8.5 weeks vs. 17.1 weeks) for
patients treated with MIS vs. open surgery, while Parker 2012 described 90% of patients who
received MIS TLIF returning to work postoperatively vs. 80% of patients treated with open
surgery. In another study, 97% of patients who were working prior to MIS TLIF were able to
return to work postoperatively [21].
The range of fusion success rate (89.6%–100.0%), regardless of how it was measured, was
similar to that of published literature using minimally invasive and open techniques [3-4, 7, 11-
12, 20, 22].  The monitoring of our study allowed us to closely follow up the safety of the device
and procedures. The majority of surgical procedures in this study was achieved with minimal
short- or long-term complications. Throughout the study, 3 out of 50 (1.19%) AEs were
considered specifically MIS-related by the surgeons; out of these three AEs, one was a serious
event (severe leg pain). The majority of AEs associated with MIS reported in the literature are
site infections. We reported a 0.4% infection rate at four weeks and no deep surgical site
infections were observed at one-year follow-up. A comparable infection rate of 0.22% was
observed in retrospective studies such as a large cohort of patients (N=1274) [24] who received
MILIF. In another retrospective study (N=5170), surgical site infections were 4.6% vs. 7.0% (P
=.037) for two-level MILIF compared with open surgery, and 4.5% vs. 4.8% ( P =.77) for one-level
MILIF vs. open surgery [25], 0.6% vs. 4%, p=0.0005,  n=362 TLIF, n=1133 open TLIF [22].
Reflective of clinical practice, the majority of surgeries performed in this study included
unilateral decompression, and a minor number of surgeries were performed with the use of a
navigation system. However, the low use of navigation systems may be the cause for higher
radiation exposure (122.0 ±130.7) compared to other studies (38.7 s, 71 s, 101 s) [26-28].  In
order to minimize the exposure, it is recommended that surgeons use intermittent
fluoroscopy and keep an adequate distance from the X-ray tube [28] and navigation systems
[29]. It is important to note that the majority of procedures (75%, 189/252) were performed
using autografting, often in conjunction with an osteoconductive synthetic bone paste. The
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most common graft substitute used in combination with autograft was nanocrystal
hydroxyapatite (45.5%, 86/189). However, data was only taken from those centers that
proactively reported the types of graft substitutes used and may not be reflective of the entire
population.
Limitations of the study
The lack of a direct comparison of outcomes for a controlled group (MIS and open surgery) as
seen in randomized controlled trials (RCTs) was a limitation of the study. Our data is reflective
of the usual clinical practice of MIS around the world and collected from a non-selected patient
population by investigators who were allowed to choose the management strategies normally
available to them in their standard practice. This study shows that MILIF is a feasible
treatment for DLD, provides valuable insights on how practitioners apply MILIF in their
practice, and will facilitate the design of future studies and identify specific indications or
patient subpopulations for MILIF. The study fulfills some of the criteria for observational
studies [30] such as a large and diverse population of patients in real-world settings, allows for
the ability to detect minor treatment effects or rare complications over one year, provides
insight into the clinical context in which multiple or complex therapies are delivered and is
relatively inexpensive and can be performed rapidly. However, the study does not fulfill the
criteria of confounding or selection bias of patients despite the defined inclusion criteria as it is
an observational study without a control. It may very well be that the surgeons only selected in
their view the 'best' patient for the surgical procedure as in 'real clinical practice'.
Successes of the study
The study assembled a large group of experienced and willing surgeons to participate in the
study. The study was monitored by an independent agency, and the study protocol was decided
well in advance. Research nurses were available for data quality and data gathering as little data
is missing, and there is a low dropout rate as only 19 patients of 252 dropped out over the
course of one year. The short-term results over one year are in line with the literature of other
spinal surgeries for DDD. Important data for patients and surgeons was gathered and useful
data for the clinical community has been presented. Future studies will have to support or
refute the outcomes of this study.
Conclusions
This is the first pragmatic, international, multicenter, prospective, monitored outcomes study
evaluating MILIF to treat DLD under usual surgical practice and to monitor progress over the
course of one year. Statistically significant and consistent results were observed for all PROs;
patients achieved early mobility, decreased leg and back pain, decreased disability, high patient
satisfaction, and more were able to work postoperatively than had been working prior to
surgery. This study shows that improvements which were observed four weeks post-surgery
were maintained or further improved up to one year with complications. The results suggest
that MILIF is an effective, feasible, and safe treatment for DLD in a broad patient population
under usual clinical conditions. Further investigation in a larger patient population will provide
insights on the long-term benefits of MILIF.
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